Mukherjee S Mimi, Dawson Aimee
MCPHS University - School of Pharmacy, Worcester, MA, USA.
Drugs Context. 2022 Jun 14;11. doi: 10.7573/dic.2021-9-12. eCollection 2022.
Due to worldwide increases in obesity and average maternal age, the incidence of gestational diabetes mellitus (GDM) is increasing. The primary treatment of GDM is medical nutrition therapy but approximately 15-30% of individuals need pharmacotherapy to reach blood glucose goals to minimize the adverse consequences of hyperglycaemia. In the past, regular and neutral protamine Hagedorn insulin were the mainstays of pharmacological treatment for GDM due to their well-established safety; however, because they are administered as injections and require strict timing of doses and meals to minimize hypoglycaemia, alternatives are often sought. The research around the treatment of GDM continues to evolve as insulin analogues and oral agents are studied in clinical trials. The short-term and long-term effects of treatment choices on both mothers and progeny are being evaluated, and this narrative review summarizes the current state of information available regarding the treatment of GDM.
由于全球肥胖率上升和孕产妇平均年龄增加,妊娠期糖尿病(GDM)的发病率正在上升。GDM的主要治疗方法是医学营养治疗,但约15-30%的患者需要药物治疗才能达到血糖目标,以尽量减少高血糖的不良后果。过去,由于常规胰岛素和中性鱼精蛋白锌胰岛素安全性良好,它们一直是GDM药物治疗的主要手段;然而,由于它们需注射给药,且需要严格控制剂量和进餐时间以尽量减少低血糖发生,人们常常寻求替代药物。随着胰岛素类似物和口服药物在临床试验中的研究,GDM治疗方面的研究不断发展。正在评估治疗选择对母亲和后代的短期和长期影响,本叙述性综述总结了GDM治疗方面的现有信息状况。